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Uveal melanoma differs from cutaneous melanoma with respect to aetiology, metastatic behaviour and immune biology. The notion
that loss of classical MHC class I molecules in uveal melanoma lesions is associated with an improved prognosis suggests that NK cells
act as the predominant cells responsible for immune surveillance of this tumour. Consequently, immune escape mechanisms of uveal
melanoma should impair the innate immunity. To this end, expression of the ligand for the NK receptor NKG2D, that is, MIC-A/B
was expressed by 50% of primary tumours, but none of the metastatic lesions. MIC
þ tumours were characterised by a NKG2D
þ
infiltrate, which was absent in MIC
  lesions subsequent to chemoimmune therapy. Strikingly, MIC-A/B expression in metastatic
lesions was observed subsequent to chemotherapy with fotemustine in one case. In summary, MIC/NKG2D interactions seem to be
involved in the immune surveillance of primary uveal melanomas, whereas for metastatic tumours this ligand/receptor system seems
not to be relevant, thus, suggesting an immune selection of MIC negative tumour cells.
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Most malignant melanomas in the ocular region arise in the uveal
tract. Little is known about its underlying molecular pathogenesis
since no genes and tumour-suppressor pathways have so far been
convincingly linked to it (Edmunds et al, 2002). The annual
incidence of uveal melanoma is in the range of 0.47–0.79 new
cases per 100000 individuals (Woll et al, 1999). Despite its lower
incidence compared to cutaneous melanoma, uveal melanoma
accounts for about 13% of all deaths from melanoma (Albert et al,
1992). Uveal melanoma preferentially disseminates haematogen-
ously to the liver and occurrence of metastases is associated with a
median survival time of less than 5 months (Eskelin et al, 1999).
For cutaneous melanoma substantial advances in the under-
standing of its pathogenesis have been achieved (Chin et al, 1998).
Among these is the recent detection of mutations in the BRAF gene
(Davies et al, 2002). Notably, BRAF is not mutated in uveal
melanoma (Edmunds and Kelsell, 2002; Cohen et al, 2003), which
highlights the molecular differences between uveal and cutaneous
melanoma and may explain both the different metastatic
behaviour as well as immune biology of these tumours (Naus
et al, 2000; Soufir et al, 2000). This could, for example, be the
consequence of reduced HLA class I antigen expression; a decrease
thereof in cutaneous melanoma is characteristic for tumour
progression and represents an important tumour escape mechan-
ism (Garrido et al, 1993; Hicklin et al, 1999). Although almost all
possible HLA class I antigen loss described for cutaneous
melanoma (Algarra et al, 2000) may occur in uveal melanomas
(Jager et al, 2002), it is important to note that metastases of uveal
melanoma have a similar or even an increased expression of MHC
molecules as compared to the primary tumour (Blom et al, 1997b).
Moreover, loss of HLA class-I expression in primary tumours is
associated with an improved survival and a lower occurrence of
metastases (Blom et al, 1997a; Ksander and Chen, 1999; Ericsson
et al, 2001). Since loss of HLA class I antigens renders cells more
sensitive to NK cell mediated lysis, it has been speculated that the
immune surveillance of uveal melanomas is based on NK cells
(Rothenfusser et al, 2002).
Over the past years it has been established that activating and
inhibiting MHC-specific receptors regulate the activity of NK cells.
In this respect, NKG2D differs from most other receptors as it
exists only in an activating form. The activating killer receptor
NKG2D is expressed on both a/b and g/d T-cells as well as NK cells
(Groh et al, 2001). The MHC class I related chain (MIC)-A/B
molecules were recently identified as ligands for this receptor. The
MIC molecules possess a low degree of homology to other MHC
class-I encoded genes (Bahram, 2000). Unlike classical class I
molecules MIC-A/B are not associated with b2-microglobulin and
do not bind peptide. MIC-A/B is highly polymorphic in its
transmembrane and extracellular region (Stephens, 2001; Collins
et al, 2002), and only some MIC-A/B variants are indeed expressed
on the cell surface. Our recent observation that primary cutaneous
melanoma expresses MIC-A/B and that this expression is down-
regulated in metastatic lesions (Vetter et al, 2002) prompted us to
scrutinise MIC-A/B expression on uveal melanoma. To this end,
we demonstrate stage-dependent expression of MIC-A/B in uveal
melanoma.
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Tissue samples
Tumour specimens of primary and metastatic uveal melanoma
were obtained by surgical excision. The representative parts of the
lesions were used for histological diagnosis and the immediate,
next slides were used for scientific workup. Informed consent was
obtained from all patients prior to any of these measures. The
clinical course of the patients is summarised in Table 1.
Immunohistochemistry
In total, 5mm sections of paraffin embedded tumours were treated
two times with xylol for 10min at room temperature. Subse-
quently, sections were washed three times with ethanol followed by
one rinse with distilled water. For antigen retrieval, sections were
incubated with citrate buffer, pH 6.0 (DAKO, Hamburg, Germany)
for 30min at 901C and then air dried for 20min at room
temperature. Next, slides were rinsed twice with phosphate-
buffered saline (PBS, DAKO, S3024) and thereafter incubated with
Blocking Solution (DAKO, S2023) for 10min at room temperature.
After two additional washing steps with PBS for 10min at room
temperature each, the respective primary monoclonal antibodies
(mAb) in PBS/1% bovine serum albumin (BSA) were added to the
sections, which were then incubated for 30min at room
temperature. The following mAb were used: MIC-A/B (6D4,
murine IgG1), NKG2D (5C6), CD57 (Klon NK-1, Zytomed, Berlin,
Germany), CD8 (DAKO, Hamburg, Germany), CD3 (DAKO,
Hamburg, Germany); the respective predetermined dilutions
ranged from 1:50 to 1:800. After two washes with PBS for
10min each, biotinylated species-specific secondary Ab (Dako)
were added to the sections. After 25min the slides were washed
twice with PBS/BSA, and finally the bound antibodies were
visualised using streptavidin-HRP or -AEC (DAKO) according to
the manufacturer’s guidelines.
Histological evaluation and scores were assessed by independent
observers (CSV and JCB) to ensure accuracy of quantification of
immunohistochemical slides. During a simultaneous session, two
observers using the same scale subsequently counted the positive
cells per perspective in high-power magnification. A total of 500
cells were examined in at least five areas and the percentage of
positive cells was determined to one of the following categories:  :
none, (þ): single, þ: 440%, þþ: 480% positive cells (Lo et al,
2003).
The mAb used for MIC-A/B (6D4) and NKG2D (5C6) were
kindly provided by Veronica Groh and Thomas Spies, Fred
Hutchinson Cancer Research Center, Seattle, USA and its
characteristics have been described (Bauer et al, 1999; Groh et al,
1999, 2003; Steinle et al, 2001).
RESULTS AND DISCUSSION
Nine primary uveal melanomas and 11 metastases were analysed
by immunohistochemistry for MIC-A/B and NKG2D expression
(Figure 1). It should be noted that we did not perform a
Table 1 Clinical course of patients with metastatic lesions
Identifier Primary tumour and therapy Metastases Therapy Death
4330/99
2854/99
1/96 enucleation 6/98 liver metastases
1/99 lung metastases
Fotemustine treosulphan/gemcitabine 1/00
800/98 3/91 enucleation 1/96 spleen metastases
8/96 liver metastases
Splenectomie interferon fotemustine Date last seen 10/97
8202/97 96 9/96 liver and lung metastases Fotemustine, IL-2 dacarbacin 1/98
9057/97b 12/89 radiation 8/94 lung metastases
97 abdominal metastases
98 brain metastases
Combined IL-2 and interferon alpha
polychemotherapy
98
9059/97 91 5/97 skin and liver metastases
98 bone metastases
Fotemustine IL-2
Interferon alpha
11/98
1709/94 87 operation 9/93 brain, lung, liver metastases Radiatio fotemustine 1/95
5368/92 87 2/92 liver metastases
11/92 cutaneous metastases
Interferon alpha
McClay
5/93
15/99-2 1/99 enucleation 6/00 liver and lung metastases Treosulphan and gemcitabine
10/01 fotemustine
9/02
Figure 1 Expression of MIC (A and B), on two primary uveal
melanomas in relation to the presence of infiltrating lymphocytes CD57
(E and F) and the expression of the activating killer receptor NKG2D
(C and D).
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metastatic lesions.
We detected MIC-A/B expression on 50% of the primary
tumours (Table 2). The corresponding receptor NKG2D was
expressed on a subset of tumour infiltrating lymphocytes present
in all MIC
þ tumours (Table 2). The NK cell marker CD57 was
present on majority of infiltrating cells in the MIC/NKG2D positive
primary tumours (Figure 1). Interestingly, the magnitude of the
inflammatory infiltrate directly correlated with the expression of
MIC-A/B on the tumour cells.
In contrast, none of the 10 cutaneous metastases from untreated
patients expressed MIC-A/B (Table 3). However, the magnitude of
the inflammatory infiltrate in metastases was not correlated with
the presence of MIC. This infiltrate largely consisted of CD3
þ cells,
but in 50% of the metastases a considerable number of CD57þ
cells were present (Figure 2). Notably, none of these infiltrating
cells expressed NKG2D. Due to the small number of cases we did
not perform statistical analysis to correlate MIC-A/B and the
magnitude of infiltrate, in order not to overestimate the power of
our observation.
The quest to establish an effective therapy for metastatic
melanoma still remains ajar. This notion holds true particularly
for disseminated uveal melanoma, since improvements of the
treatment of primary uveal melanoma, enabling the preservation
of the eye and its visual function, has not reduced the rate of
subsequent tumour dissemination. The range of therapeutic
options for stage IV disease encompasses chemotherapeutic,
immune, antiangiogenic, and hormonal strategies or a combina-
tion thereof. Although the rationale for such combinations, for
example chemo-immune therapy, is mostly empiric chemo-
immune therapy still is the most promising approach. Notably,
the sequence in which chemo- and immune therapies are given,
that is, first chemotherapy followed by immunotherapy or vice
versa, strongly correlates with the therapeutic activity. The
synergistic effect of this combination may be explained by the
chemotherapy-induced expression of stress-induced molecules, for
example MIC-A/B, on tumour cells, which serve as targets for
immune stimulatory molecules such as NKG2D expressed on NK-,
T- and NK/T-cells.
We were able to analyse two metastases from one patient,
which had been obtained prior and subsequent to therapy
with fotemustine, interferon a and IL2. Notably, prior to
chemotherapy neither MIC-A/B nor its receptor NKG2D was
detectable in the tumour lesion. After two courses of therapy,
however, another subcutaneous metastasis from the same patient
was characterised by an intense expression of MIC-A/B on more
than 10% of the tumour cells. This metastasis was further
characterised by a dense inflammatory infiltrate of CD3- and
CD57-positive cells. This infiltrate also stained positive for
NKG2D. Although it cannot be proved that these differences are
merely due to lesion heterogeneity, the constant lack of MIC-A/B
in all patients not receiving chemotherapy strongly suggests that
Table 2 Uveal melanoma – primary tumours
MIC-A/B
b NKG 2-D
c CD 57
c
No. TIL
a Frequency Intensity Frequency Intensity Frequency Intensity
401/99 Ø    
331/99 (+) +
d + + (+) (+) +
133/99 (+) (+) (+) (+) + (+) +
15/99 +    
346/98 Ø    
401/97 (+)    
290/97 (+) ++ + ++ + ++ +
269/97 (+) + + + + + +
120/92 + + + + (+) + +
aThe inflammatory infiltrate is classified according to the criteria of Elder and Clark as ++: brisk; +: nonbrisk; (+): dim; Ø: absent.
bExpression on melanoma cells.
cExpression on
tumour infiltrating lymphocytes.
d : none, (+): single, +: o40%, ++: o80% positive cells.
Table 3 Uveal melanoma – metastases
MIC-A/B
b NKG 2-D
c
CD57
c CD3
c
No. TIL
a Frequency Intensity Frequency Intensity Frequency Frequency
2616/99 (+) – – – +
2854/99
d (+) – – – (+)
4430/99 + +
e ++ ++ + + ++
800/98 (+) – – + +
8202/97 (+) – – – (+)
9057/97 (+) – – + ++
9059/97 (+) – – + +
1709/94 ++ – – – –
3713/95 (+) – – – +
6830/95 (+) – – (+) +
7602/95 (+) – – – (+)
5368/92 + – – (+) –
aThe inflammatory infiltrate is classified according to the criteria of Elder and Clark as ++: brisk; +: nonbrisk; (+): dim; Ø: absent.
bExpression on melanoma cells.
cExpression on
tumour infiltrating lymphocytes.
d#2854/99 and 4430/99 were obtained from the same patient prior or after therapy with fotemustine.
e : none, (+): single, +: o40%, ++:
o80% positive cells.
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measures.
The lack of correlation of melanoma-specific immune responses
and the clinical course of the disease has provided the impetus to
investigate the mechanisms used by malignant cells to escape
immune recognition. In this respect, abnormalities in HLA class I
expression have been conclusively demonstrated as one of these
mechanisms (Campoli et al, 2002). Since NK cell lysis is enhanced
by downregulated MHC class I expression, Uveal melanoma may
actually represent an exception to this rule (Seliger et al, 2003).
Indeed, Ma et al (1995) demonstrated that the sensitivity of human
uveal melanoma cells to NK cell lysis was reciprocal to the level of
HLA class I expression. Susceptibility to NK lysis also impacts the
metastatic behaviour: injection of uveal melanoma cells into eyes
of nude mice demonstrated an inverse correlation between
development of hepatic metastases and the sensitivity of cell lysis
in vitro (Ma and Niederkorn, 1995).
Since NK cells infringe in immune surveillance of uveal
melanoma, immunotherapy for these tumours should include
strategies influence them and therefore innate immunity. The
interaction of NKG2D with MIC-A/B may serve this approach. The
MIC gene transcriptional regulatory sequences contain heat-shock
elements similar to those in the human Hsp70 promoter. Since
genotoxic chemotherapeutic agents such as alkylating, cytotoxic,
antimitotic and antimetabolic substances, activate the Hsp70
promoter (Hunt and Morimoto, 1985; Groh et al, 1996) via
binding of HSF-1, thereby inducing gene transcription, similar
mechanisms, may explain the induction of MIC-A/B expression by
fotemustine (Liu et al, 1996). Though induction of MIC-A/B by
chemotherapy and subsequent presence of an NKG2D
þ inflam-
matory infiltrate was only investigated in one patient, our previous
studies in cutaneous melanoma demonstrated changes in the
inflammatory infiltrates at different tumour stages, which were
associated with changes in MIC-A/B expression (Vetter et al,
2002), thus strengthening the relevance of these findings in this
one patient.
In conclusion, MIC/NKG2D interactions are present in the
initial phases of an immune response to uveal melanoma, but this
interaction seems to be less involved in responses to metastatic
disease suggesting immune selection of MIC negative tumour cells.
However, cell stresses such as the presence of different cytotoxic
agents seem to restore MIC-A/B expression. Even if this notion is
based on a case report, it is of particular interest as it links chemo-
and immunotherapy and explains the synergistic effects of these
different therapeutic approaches empirically established in the
clinic (Woll et al, 1999).
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